Amgen's Phase III ABP 501 trial in rheumatoid arthritis patients meets endpoints

US-based biopharmaceutical firm Amgen has reported positive results from its Phase III trial of biosimilar candidate ABP 501 compared with Humira (adalimumab) in patients with moderate-to-severe rheumatoid arthritis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news